37 70

Cited 0 times in

Factors Related to Major Bleeding After Ticagrelor Therapy: Results from the TICO Trial

Authors
 Jae Young Cho  ;  Seung-Yul Lee  ;  Kyeong Ho Yun  ;  Byeong-Keuk Kim  ;  Sung-Jin Hong  ;  Jum Suk Ko  ;  Sang Jae Rhee  ;  Seok Kyu Oh  ;  Dong-Ho Shin  ;  Chul-Min Ahn  ;  Jung-Sun Kim  ;  Young-Guk Ko  ;  Donghoon Choi  ;  Myeong-Ki Hong  ;  Yangsoo Jang 
Citation
 JOURNAL OF THE AMERICAN HEART ASSOCIATION, Vol.10(7) : e19630, 2021-04 
Journal Title
JOURNAL OF THE AMERICAN HEART ASSOCIATION
Issue Date
2021-04
MeSH
Acute Coronary Syndrome / therapy* ; Aged ; Drug-Eluting Stents* ; Female ; Follow-Up Studies ; Humans ; Incidence ; Male ; Middle Aged ; Percutaneous Coronary Intervention / adverse effects* ; Postoperative Hemorrhage / chemically induced* ; Postoperative Hemorrhage / epidemiology ; Republic of Korea / epidemiology ; Risk Factors ; Sirolimus / pharmacology* ; Ticagrelor / administration & dosage ; Ticagrelor / adverse effects* ; Time Factors
Keywords
acute coronary syndrome ; antiplatelet therapy ; drug‐eluting stent
Abstract
Background There is a lack of data on factors that are related to clinically relevant bleeding after ticagrelor treatment. We investigated the clinical and procedural factors related to major bleeding in patients with acute coronary syndrome treated with ticagrelor after coronary stent implantation. Methods and Results From the TICO (Ticagrelor Monotherapy After 3 Months in Patients Treated With New Generation Sirolimus-Eluting Stent for Acute Coronary Syndrome) randomized trial, a total of 2660 patients were included for the present study. Patients with major bleeding, defined by TIMI (Thrombolysis in Myocardial Infarction) major or Bleeding Academic Research Consortium type 3 or 5, were compared with those without major bleeding. On the basis of multivariable and receiver operating characteristic curve analyses, weight ≤65 kg, hemoglobin ≤12 g/dL, and estimated glomerular filtration rate <60 mL/min per 1.73 m2 were associated with an increased risk of major bleeding. In contrast, 3-month aspirin therapy with continued ticagrelor (versus 12-month aspirin and ticagrelor) was associated with a decreased risk of major bleeding. The lower risk of a net adverse clinical event (a composite of TIMI major bleeding and major adverse cardiac and cerebrovascular events) in patients treated with 3-month aspirin therapy reported from the TICO trial remained valid in patients with any of these risk factors (hazard ratio, 0.59; 95% CI, 0.39-0.90; Pinteraction=0.74). Conclusions Low body weight, anemia, and chronic kidney disease were risk factors for major bleeding after ticagrelor therapy. Early aspirin discontinuation had a net clinical benefit among patients with a bleeding risk. Registration URL: https://www.clinicaltrials.gov/. Unique Identifier: NCT02494895.
Files in This Item:
T202104786.pdf Download
DOI
10.1161/JAHA.120.019630
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Ko, Young Guk(고영국) ORCID logo https://orcid.org/0000-0001-7748-5788
Kim, Byeong Keuk(김병극) ORCID logo https://orcid.org/0000-0003-2493-066X
Kim, Jung Sun(김중선) ORCID logo https://orcid.org/0000-0003-2263-3274
Ahn, Chul-Min(안철민) ORCID logo https://orcid.org/0000-0002-7071-4370
Jang, Yang Soo(장양수) ORCID logo https://orcid.org/0000-0002-2169-3112
Choi, Dong Hoon(최동훈) ORCID logo https://orcid.org/0000-0002-2009-9760
Hong, Myeong Ki(홍명기) ORCID logo https://orcid.org/0000-0002-2090-2031
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/186885
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links